Platelet/lymphocyte ratio for prediction of no-reflow phenomenon in ST-elevation myocardial infarction managed with primary percutaneous coronary intervention
Background: Coronary no-reflow phenomenon in ST-segment elevation myocardial infarction (STEMI) is associated with a poor clinical outcome. Although its pathophysiology is not fully understood, a deregulated systemic inflammatory response plays an important role. We aimed to explore the relationship between platelet\lymphocyte ratio (PLR) and no-reflow in patients with acute STEMI who were treated with primary percutaneous coronary intervention (PPCI).
Methods: A total of 200 patients with STEMI undergoing primary PCI were included in the study. Transthoracic echocardiographic examination was performed to assess left ventricular (LV) ejection fraction and wall motion score index. Blood samples were assayed for platelet and lymphocyte count before primary PCI. No-reflow was defined as coronary blood flow TIMI grade ≤ II.
Results: No-reflow was observed in 58 (29%) of STEMI patients following PPCI. PLR was significantly higher in hypertensive patients compared to normotensive patients (144.7 ± 91.6 vs. 109.1 ± 47.1, respectively, P < 0.001) and in the no-reflow group compared to the normal reflow group (214 ± 93 vs. 101.6 ± 51.3, respectively, P < 0.0001). Logistic regression analysis revealed that PLR (β: 0.485, 95% CI: -0.006 - 0.001, P < 0.002) and LV ejection fraction (β: 0.272, 95% CI: 0.009 - 0.034, P < 0.001) were independent predictors of no-reflow after primary PCI.
Conclusion: Pre-procedural increase in PLR is predictive of the no-reflow phenomenon following primary PCI in STEMI patients.
Relevance for patients: No reflow phenomenon is an unfavorable complication following primary PCI in patients with acute STEMI. High pre-procedural PLR is an independent predictor of reperfusion failure and helps to identify patients who require prophylactic treatment.
[1] O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr., Chung MK, de Lemos JA, et al. ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78-140.
[2] O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr., Chung MK, de Lemos JA, et al. ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-425.
[3] Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, et al. Incidence and Treatment of NoReflow after Percutaneous Coronary Intervention. Circulation 1994;89:2514-8.
[4] Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, et al. No-reflow is An Independent Predictor of Death and Myocardial Infarction after Percutaneous Coronary Intervention. Am Heart J 2003;145:42-6.
[5] Harrison RW, Aggarwal A, Ou FS, Klein LW, Rumsfeld JS, Roe MT, et al. Incidence and Outcomes of No-Reflow Phenomenon During Percutaneous Coronary Intervention Among Patients with Acute Myocardial Infarction. Am J Cardiol 2013;111:178-84.
[6] Galiuto L. Optimal Therapeutic Strategies in the Setting of Post-Infarct No Reflow: The Need for a Pathological Classification. Heart 2004;90:123-5.
[7] Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular Obstruction and the No-Reflow Phenomenon after Percutaneous Coronary Intervention. Circulation 2008;117:3152-6.
[8] Dong-Bao L, Qi H, Zhi L, Wei-Ying J. Predictors and Long-Term Prognosis of Angiographic Slow/No-Reflow Phenomenon During Emergency Percutaneous Coronary Intervention for ST-Elevated Acute Myocardial Infarction. Clin Cardiol 2010;33:E7-12.
[9] Karimianpour A, Maran A. Advances in Coronary NoReflow Phenomenon-A Contemporary Review. Curr Atheroscler Rep 2018;20:44.
[10] Gupta S, Gupta M. No Re-Flow Phenomenon in Percutaneous Coronary Interventions in ST-Segment Elevation Myocardial Infarction. Indian Heart J 2016;68:539-51.
[11] Wang K, Zhang J, Zhang N, Shen Y, Wang L, Gu R, et al. Combined Primary PCI with Multiple Thrombus Burden Reduction Therapy Improved Cardiac Function in Patients with Acute Anterior Myocardial Infarction. Int Heart J 2019;60:27-36.
[12] Zhou H, He XY, Zhuang SW, Zhuang SW, Wang J, Lai Y, et al. Clinical and Procedural Predictors of No-Reflow in Patients with Acute Myocardial Infarction after Primary Percutaneous Coronary Intervention. World J Emerg Med 2014;5:96-102.
[13] Wang J, Chen Y, Wang C, Yang XC, Zhu XL, Zhou ZQ. Development and Validation of a Clinical Risk Score Predicting the No-Reflow Phenomenon in Patients Treated with Primary Percutaneous Coronary Intervention for STSegment Elevation Myocardial Infarction. Cardiology 2013;124:153-60.
[14] Bouleti C, Mewton N, Germain S. The No-Reflow Phenomenon: State of the Art. Arch Cardiovasc Dis 2015;108:661-74.
[15] Watanabe Y, Sakakura K, Taniguchi Y, Yamamoto KK, Wada H, Momomura S, et al. Determinants of Slow Flow in Percutaneous Coronary Intervention to the Culprit Lesion of Non-ST Elevation Myocardial Infarction. Int Heart J 2018;59:1237-45.
[16] Fabris E, Kilic S, Schellings DA, Berg JM, Kennedy MW, van Houwelingen KG, et al. Long-Term Mortality and Prehospital Tirofiban Treatment in Patients with ST Elevation Myocardial Infarction. Heart 2017;103:1515-20.
[17] Pekdemir H, Polat G, Cin VG, Camsari A, Cicek D, Akkus MN, et al. Elevated Plasma Endothelin-1 Levels in Coronary Sinus During Rapid Right Atrial Pacing in Patients with Slow Coronary Flow. Int J Cardiol 2004;97:35-41.
[18] Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood Platelet Count and Function are Related to Total and Cardiovascular Death in Apparently Healthy Men. Circulation 1991;84:613-7.
[19] Iijima R, Ndrepepa G, Mehilli J, Bruskina O, Schulz S, Schömig A, et al. Relationship Between Platelet Count and 30-Day Clinical Outcomes after Percutaneous Coronary Interventions. Pooled Analysis of Four ISAR Trials. Thromb Haemost 2007;98:852-7.
[20] Vidwan P, Lee S, Rossi JS, Stouffer GA. Relation of Platelet Count to Bleeding and Vascular Complications in Patients Undergoing Coronary Angiography. Am J Cardiol 2010;105:1219-22.
[21] Ommen SR, Hammill SC, Gibbons RJ. The Relative Lymphocyte Count Predicts Death in Patients Receiving Implantable Cardioverter Defibrillators. Pacing Clin Electrophysiol 2002;25:1424-8.
[22] Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP. Prognosis of Resected Ampullary Adenocarcinoma by Preoperative Serum CA19-9 Levels and Platelet-Lymphocyte Ratio. J Gastrointest Surg 2008;12:1422-8.
[23] Wang D, Yang JX, Cao DY, Wan XV, Feng FZ, Huang HF, et al. Preoperative Neutrophil-Lymphocyte and PlateletLymphocyte Ratios as Independent Predictors of Cervical Stromal Involvement in Surgically Treated Endometrioid Adenocarcinoma. Onco Targets Ther 2013;6:211-6.
[24] Kaya MG, Uyarel H, Akpek M, Kalay N, Ergelen M, AyhanE, et al. Prognostic Value of Uric Acid in Patients with ST-Elevated Myocardial Infarction Undergoing Primary Coronary Intervention. Am J Cardiol 2012;109:486-91.
[25] Akpek M, Kaya MG, Yarlioglues M, Dogdu O, Ardic I, Sahin O, et al. Relationship Between Platelet Indices and Spontaneous Echo Contrast in Patients with Mitral Stenosis. Eur Echocardiogr 2011;12:865-70.
[26] Kaya MG, Akpek M, Elcik D, Kalay N, Yarlioglues M, Koc F, et al. Relation of Left Atrial Spontaneous Echocardiographic Contrast in Patients with Mitral Stenosis to Inflammatory Markers. Am J Cardiol 2012;109:851-5.
[27] Krenn-Pilko S, Langsenlehner U, Thurner EM, StojakovicT, Pichler M, Gerger A, et al. The Elevated Preoperative Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis in Breast Cancer Patients. Br J Cancer 2014;110:2524-30.
[28] Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera Badillo FE, Hermanns T, et al. Prognostic role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev 2014;23:1204-12.
[29] Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, et al. Increased Platelet Reactivity and Circulating Monocyte-Platelet Aggregates in Patients with Stable Coronary Artery Disease. J Am Coll Cardiol 1998;31:352-8.
[30] Ault KA, Cannon CP, Mitchell J, Cahan J, Tracy RP, Novotny WF, et al. Platelet Activation in Patients after an Acute Coronary Syndrome: Results from the TIMI-12 Trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999;33:634-9.
[31] Kurtul A, Murat SN, Yarlioglues M, Duran M, Ergun G, Acikgoz SK, et al. Association of Platelet-to-Lymphocyte Ratio with Severity and Complexity of Coronary Artery Disease in Patients with Acute Coronary Syndromes. Am J Cardiol 2014;114:972-8.
[32] Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as Predictors of Vascular Risk: Is there a Practical Index of Platelet Activity? Clin Appl Thromb Hemost 2003;9:177-90.
[33] Zouridakis EG, Garcia-Moll X, Kaski JC. Usefulness of the Blood Lymphocyte Count in Predicting Recurrent Instability and Death in Patients with Unstable Angina Pectoris. Am J Cardiol 2000;86:449-51.
[34] Li H, Zhou Y, Ma Y, Han S, Zhou L. The Prognostic Value of the Platelet: Lymphocyte Ratio in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. Kardiol Pol 2017;75:666-73.
[35] Azab B, Shah N, Akerman M, Han S, Zhou L. Value of Platelet/Lymphocyte Ratio as a Predictor of All-Cause Mortality after Non-ST-Elevation Myocardial Infarction. J Thromb Thrombolysis 2012;34:326-34.
[36] Osadnik T, Wasilewski J, Lekston A, Strzelczyk J, KurekA, Gonera M, et al. The Platelet-to-Lymphocyte Ratio as a Predictor of All-Cause Mortality in Patients with Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention and Stent Implantation. J Saudi Heart Assoc 2015;27:144-51.
[37] Cho KI, Ann SH, Singh GB, Her AV, Shin ES. Combined Usefulness of the Platelet-to- Lymphocyte Ratio and the Neutrophil-to-Lymphocyte Ratio in Predicting the LongTerm Adverse Events in Patients Who Have Undergone Percutaneous Coronary Intervention with a Drug-Eluting Stent. PLoS One 2015;10:e0133934.
[38] Akasaka T, Yoshida K, Kawamoto T, Kaji S, Ueda Y, Yamamuro A, et al. Relation of Phasic Coronary Flow Velocity Characteristics with TIMI Perfusion Grade and Myocardial Recovery after Primary Percutaneous Transluminal Coronary Angioplasty and Rescue Stenting. Circulation 2000;101:2361-7.
[39] Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, et al. Distal Microcirculatory Protection During Percutaneous Coronary Intervention in Acute STSegment Elevation Myocardial Infarction: A Randomized Controlled Trial. JAMA 2005;293:1063-72.